(Q36876028)

16 August 2017

Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand (English)

1 reference

16 August 2017

0 references

0 references

1 reference

Jacques LeLorier

1

1 reference

PMC publication ID

2651914

16 August 2017

Nugek S B Rawson

series ordinal

2

1 reference

16 August 2017

1 July 2007

1 reference

The Canadian Journal of Cardiology

16 August 2017

1 reference

16 August 2017

23

1 reference

16 August 2017

9

1 reference

16 August 2017

711-718

1 reference

PHARMAC and the statin debacle

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

How low can it go? Projecting ischaemic heart disease mortality in New Zealand to 2015

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

PHARMAC and lack of funding for clopidogrel

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

The Common Drug Review: a NICE start for Canada?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

PHARMAC and Ventolin in New Zealand.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Management of patients admitted with an Acute Coronary Syndrome in New Zealand: results of a comprehensive nationwide audit

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Health expenditure trends in OECD countries, 1990-2001

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: a personal viewpoint.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Reimbursement of pharmaceuticals in New Zealand: comments on PHARMAC's processes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Reference pricing--is it in the public interest?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Excess coronary mortality among Australian men and women living outside the capital city statistical divisions.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Canadian health expenditures: where do we really stand internationally?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Data for evaluating drugs is often poor, say experts

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

The impact of reference pricing on clinical lipid control

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Declining rates of coronary heart disease in New Zealand and Australia, 1983-1993.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Changes in cardiovascular deaths and hospitalization in Canada

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

PHARMAC's response on clopidogrel.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Economic burden of cardiovascular diseases in the enlarged European Union

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

PHARMAC responds on long-acting inhalers for COPD

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Heart attacks and unstable angina (acute coronary syndromes) have doubled in New Zealand since 1989: how do we best manage the epidemic?

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Long-acting inhaled bronchodilators for COPD--lack of logic continues.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

PHARMAC responds on salbutamol

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Dihydropyridines, felodipine, and PHARMAC.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Pharmacological treatment of congestive heart failure in Canada: a description of care in five provinces.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Cardiac rehabilitation services in New Zealand: access and utilisation.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Acute Coronary Syndrome patients in New Zealand receive less invasive management when admitted to hospitals without invasive facilities.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Quality and equity in cardiovascular health in New Zealand: the need for agreed achievable standards of care, cohesive planning, and action

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Risk factors for cardiovascular disease in Canada.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Response from PHARMAC: difficult choices

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

A dog's breakfast: prescription drug coverage varies widely across Canada

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

Regional revascularization patterns after myocardial infarction in Ontario

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651914

4 September 2018

1 reference

12 December 2020

Mortality from cardiovascular disease is too high outside capital cities

1 reference

12 December 2020

PHARMAC Mark 2: towards agreed solutions?

1 reference

12 December 2020

Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates

1 reference

12 December 2020

Health services at breaking point. ...don't panic?

1 reference

12 December 2020

Heart failure: ethnic disparities in morbidity and mortality in New Zealand

1 reference

12 December 2020

Asthma in New Zealand--time to get control

1 reference

12 December 2020

Heart failure: how can we prevent the epidemic?

1 reference

12 December 2020

Achieving equity in the Australian healthcare system

1 reference

12 December 2020

The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s

1 reference

12 December 2020

Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders?

1 reference

12 December 2020

Approval process and access to prescription drugs in Canada

1 reference

12 December 2020

Is the United States an outlier in health care and health outcomes? A preliminary analysis

1 reference

12 December 2020

Heart health has an adverse future forecast in New Zealand: an alarm call to action across the continuum

1 reference

12 December 2020

Fluvastatin: what is the evidence?

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Lipid-modifying drugs

1 reference

12 December 2020

Increased thrombotic vascular events after change of statin

1 reference

12 December 2020

10.1016/S0828-282X(07)70815-2

Identifiers

DOI

1 reference

16 August 2017

1 reference

PMC publication ID

2651914

16 August 2017

PubMed publication ID

17622393

1 reference

PMC publication ID

2651914